Filing Flows › Comparisons › ENTX vs SNTI
Entera Bio vs Senti Biosciences Holdings: ENTX and SNTI compared
Entera Bio is the larger company: $42K of revenue in its latest quarter (Q1 2025) against $17K for Senti Biosciences Holdings (Q2 2026).
Where the money goes: ENTX and SNTI
Entera Bio (ENTX) · Q1 2025
Entera Bio, Q1 2025: revenue $42K, net loss $2.6M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
Senti Biosciences Holdings (SNTI) · Q2 2026
Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Entera Bio (ENTX) | Senti Biosciences Holdings (SNTI) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q2 2026 |
| Revenue | $42K | $17K |
| Operating margin | n/m | n/m |
| Net earnings | −$2.6M | −$12.8M |
| Operating cash flow | −$1.4M | −$14.2M |
Questions
Which is bigger, Entera Bio or Senti Biosciences Holdings?
Entera Bio is the larger company: $42K of revenue in its latest quarter (Q1 2025) against $17K for Senti Biosciences Holdings (Q2 2026).
More: Entera Bio earnings · how Entera Bio makes money · Senti Biosciences Holdings earnings · how Senti Biosciences Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 9, 2025; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.